Volume 16, No 6, page 577: The Background/Aim in the abstract should read:
Abstract. Background/Aim: KRAS mutation represents the most frequent molecular alteration found in advanced non-small cell lung cancer (NSCLC). Several studies have showed the poor outcome of its prognostic role. The landscape of treatments for NSCLC has recently changed with the introduction of immune checkpoint inhibitors (ICIs), and data about their efficacy in patients with KRAS-mutant NSCLC are discordant. This study assessed the routine efficacy of ICIs in advanced KRAS-mutant NSCLC.
- Copyright © 2020 The Author(s). Published by the International Institute of Anticancer Research.
